{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:01:45Z","timestamp":1790704905207,"version":"4.1.0"},"reference-count":98,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,3,1]],"date-time":"2027-03-01T00:00:00Z","timestamp":1803859200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,3,1]],"date-time":"2027-03-01T00:00:00Z","timestamp":1803859200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,3,1]],"date-time":"2027-03-01T00:00:00Z","timestamp":1803859200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2027,3,1]],"date-time":"2027-03-01T00:00:00Z","timestamp":1803859200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2027,3,1]],"date-time":"2027-03-01T00:00:00Z","timestamp":1803859200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2027,3,1]],"date-time":"2027-03-01T00:00:00Z","timestamp":1803859200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2027,3,1]],"date-time":"2027-03-01T00:00:00Z","timestamp":1803859200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2027,3]]},"DOI":"10.1016\/j.cca.2026.122858","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T15:14:52Z","timestamp":1790608492000},"page":"122858","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["ZAP-70 as a prognostic laboratory biomarker in chronic lymphocytic leukemia: flow-cytometric assessment, clinical utility, and standardization challenges"],"prefix":"10.1016","volume":"594","author":[{"given":"Riya","family":"Thapa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj Kumar","family":"Fuloria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Zahid","family":"Iqbal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid M.","family":"Orayj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asif Ahmad","family":"Bhat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamal","family":"Narain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumita","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurabh","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anupam","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivkanya","family":"Fuloria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cca.2026.122858_bb0005","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1053\/j.seminhematol.2024.02.002","article-title":"Prognostication in chronic lymphocytic leukemia","volume":"61","author":"Moia","year":"2024","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.cca.2026.122858_bb0010","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood.V94.6.1840","article-title":"Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia","volume":"94","author":"Damle","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.cca.2026.122858_bb0015","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1182\/blood.V94.6.1848","article-title":"Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia","volume":"94","author":"Hamblin","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.cca.2026.122858_bb0020","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic aberrations and survival in chronic lymphocytic leukemia","volume":"343","author":"D\u00f6hner","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cca.2026.122858_bb0025","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1056\/NEJMoa023143","article-title":"ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia","volume":"348","author":"Crespo","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cca.2026.122858_bb0030","article-title":"Flow cytometric analysis of ZAP-70 protein expression for B-cell chronic lymphocytic leukemia prognostication: usefulness and limitations","volume":"12","author":"Shaikh","year":"2020","journal-title":"Cureus"},{"key":"10.1016\/j.cca.2026.122858_bb0035","doi-asserted-by":"crossref","first-page":"270","DOI":"10.3390\/hematolrep16020027","article-title":"Current therapeutic sequencing in chronic lymphocytic leukemia","volume":"16","author":"Mouhssine","year":"2024","journal-title":"Hematol. Rep."},{"key":"10.1016\/j.cca.2026.122858_bb0040","doi-asserted-by":"crossref","first-page":"3612","DOI":"10.1158\/1078-0432.CCR-22-3217","article-title":"CD49d expression identifies a biologically distinct subtype of chronic lymphocytic leukemia with inferior progression-free survival on BTK inhibitor therapy","volume":"29","author":"Alsadhan","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cca.2026.122858_bb0045","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1038\/s41375-024-02376-7","article-title":"The VLA-4 integrin is constitutively active in circulating chronic lymphocytic leukemia cells via BCR autonomous signaling: a novel anchor-independent mechanism exploiting soluble blood-borne ligands","volume":"38","author":"Tissino","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.cca.2026.122858_bb0050","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.70403","article-title":"EHA guidelines on management of chronic lymphocytic leukemia and Richter transformation","volume":"10","author":"Eichhorst","year":"2026","journal-title":"HemaSphere"},{"key":"10.1016\/j.cca.2026.122858_bb0055","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.128","article-title":"CD49d expression is included in a revised 4-factor model predicting outcome in patients with chronic lymphocytic leukemia treated with ibrutinib: a multicenter real-world experience","volume":"8","author":"Bomben","year":"2024","journal-title":"HemaSphere"},{"key":"10.1016\/j.cca.2026.122858_bb0060","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1182\/blood-2011-02-335125","article-title":"A unique proteomic profile on surface IgM ligation in unmutated chronic lymphocytic leukemia","volume":"118","author":"Perrot","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.cca.2026.122858_bb0065","doi-asserted-by":"crossref","first-page":"4401","DOI":"10.1182\/blood-2011-01-333682","article-title":"ZAP-70 enhances migration of malignant B lymphocytes toward CCL21 by inducing CCR7 expression via IgM-ERK1\/2 activation","volume":"118","author":"Calpe","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.cca.2026.122858_bb0070","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/leu.2009.216","article-title":"Recruitment of PKC-\u03b2II to lipid rafts mediates apoptosis-resistance in chronic lymphocytic leukemia expressing ZAP-70","volume":"24","author":"zum B\u00fcschenfelde","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.cca.2026.122858_bb0075","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.leukres.2015.04.016","article-title":"Differential expression and function of CD27 in chronic lymphocytic leukemia cells expressing ZAP-70","volume":"39","author":"Lafarge","year":"2015","journal-title":"Leuk. Res."},{"key":"10.1016\/j.cca.2026.122858_bb0080","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1158\/1078-0432.CCR-05-1531","article-title":"ZAP-70 expression in normal pro\/pre B cells, mature B cells, and in B-cell acute lymphoblastic leukemia","volume":"12","author":"Crespo","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cca.2026.122858_bb0085","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/sj.leu.2404138","article-title":"ZAP-70 is expressed by normal and malignant human B-cell subsets of different maturational stage","volume":"20","author":"Scielzo","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.cca.2026.122858_bb0090","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/cyto.b.20127","article-title":"ZAP-70 expression in B-cell chronic lymphocytic leukemia: evaluation by external (isotypic) or internal (T\/NK cells) controls and correlation with IgV(H) mutations","volume":"70","author":"Zucchetto","year":"2006","journal-title":"Cytometry B Clin. Cytom."},{"key":"10.1016\/j.cca.2026.122858_bb0095","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/ajh.27137","article-title":"Normal B cells express ZAP70 in chronic lymphocytic leukemia: a link between autoimmunity and lymphoproliferation?","volume":"99","author":"Ghergus","year":"2024","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.cca.2026.122858_bb0100","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/path.1727","article-title":"Immunohistochemical analysis of ZAP-70 expression in B-cell lymphoid neoplasms","volume":"205","author":"Carreras","year":"2005","journal-title":"J. Pathol."},{"key":"10.1016\/j.cca.2026.122858_bb0105","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/cyto.b.20149","article-title":"Comparative analysis of ZAP-70 expression and Ig VH mutational status in B-cell chronic lymphocytic leukemia","volume":"72","author":"Mu\u00f1oz","year":"2007","journal-title":"Cytometry B Clin. Cytom."},{"key":"10.1016\/j.cca.2026.122858_bb0110","doi-asserted-by":"crossref","first-page":"4944","DOI":"10.1182\/blood-2002-10-3306","article-title":"ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile","volume":"101","author":"Wiestner","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.cca.2026.122858_bb0115","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/cyto.b.20134","article-title":"Variations in the detection of ZAP-70 in chronic lymphocytic leukemia: comparison with IgV(H) mutation analysis","volume":"70","author":"Sheikholeslami","year":"2006","journal-title":"Cytometry B Clin. Cytom."},{"key":"10.1016\/j.cca.2026.122858_bb0120","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1038\/modpathol.2010.131","article-title":"Immunohistochemical detection of ZAP70 in chronic lymphocytic leukemia predicts immunoglobulin heavy chain gene mutation status and time to progression","volume":"23","author":"Admirand","year":"2010","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.cca.2026.122858_bb0125","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/cyto.b.20137","article-title":"ZAP-70 in CLL: towards standardization of a biomarker for patient management: history of clinical cytometry special issue","volume":"70","author":"Marti","year":"2006","journal-title":"Cytometry B Clin. Cytom."},{"key":"10.1016\/j.cca.2026.122858_bb0130","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/cyto.b.20132","article-title":"Evaluation of ZAP-70 expression by flow cytometry in chronic lymphocytic leukemia: a multicentric international harmonization process","volume":"70","author":"Letestu","year":"2006","journal-title":"Cytometry B Clin. Cytom."},{"key":"10.1016\/j.cca.2026.122858_bb0135","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1182\/bloodadvances.2022009557","article-title":"ZAP-70 augments tonic B-cell receptor and CCR7 signaling in IGHV-unmutated chronic lymphocytic leukemia","volume":"8","author":"Chen","year":"2024","journal-title":"Blood Adv."},{"key":"10.1016\/j.cca.2026.122858_bb0140","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1371057","article-title":"An overview of prognostic markers in patients with CLL","volume":"14","author":"Braish","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.cca.2026.122858_bb0145","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0140-6736(03)15260-9","article-title":"ZAP-70 expression and prognosis in chronic lymphocytic leukaemia","volume":"363","author":"Orchard","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.cca.2026.122858_bb0150","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1056\/NEJMoa040857","article-title":"ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia","volume":"351","author":"Rassenti","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cca.2026.122858_bb0155","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1200\/JCO.2005.03.7184","article-title":"Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia","volume":"24","author":"Kr\u00f6ber","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cca.2026.122858_bb0160","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1002\/cncr.21437","article-title":"Zeta-chain associated protein 70 and CD38 combined predict the time to first treatment in patients with chronic lymphocytic leukemia","volume":"104","author":"Del Giudice","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.cca.2026.122858_bb0165","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1182\/blood-2014-02-555722","article-title":"Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia","volume":"124","author":"Claus","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.cca.2026.122858_bb0170","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.790004","article-title":"Clonal evolution of high-risk chronic lymphocytic leukemia: a contemporary perspective","volume":"11","author":"Kwok","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.cca.2026.122858_bb0175","doi-asserted-by":"crossref","first-page":"4609","DOI":"10.1182\/blood-2002-06-1683","article-title":"Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia","volume":"100","author":"Chen","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.cca.2026.122858_bb0180","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1182\/blood-2006-03-011759","article-title":"ZAP-70 enhances B-cell-receptor signaling despite absent or inefficient tyrosine kinase activation in chronic lymphocytic leukemia and lymphoma B cells","volume":"109","author":"Gobessi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.cca.2026.122858_bb0185","doi-asserted-by":"crossref","first-page":"790","DOI":"10.3324\/haematol.2008.002626","article-title":"Gene expression profiling reveals differences in microenvironment interaction between patients with chronic lymphocytic leukemia expressing high versus low ZAP70 mRNA","volume":"94","author":"Stamatopoulos","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.cca.2026.122858_bb0190","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0081221","article-title":"ZAP-70 promotes the infiltration of malignant B-lymphocytes into the bone marrow by enhancing signaling and migration after CXCR4 stimulation","volume":"8","author":"Calpe","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.cca.2026.122858_bb0195","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2014.391","article-title":"Gefitinib targets ZAP-70-expressing chronic lymphocytic leukemia cells and inhibits B-cell receptor signaling","volume":"5","author":"Dielschneider","year":"2014","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.cca.2026.122858_bb0200","doi-asserted-by":"crossref","first-page":"12262","DOI":"10.1038\/s41598-017-12135-7","article-title":"Microenvironment regulates the expression of miR-21 and tumor suppressor genes PTEN, PIAS3 and PDCD4 through ZAP-70 in chronic lymphocytic leukemia","volume":"7","author":"Carabia","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cca.2026.122858_bb0205","article-title":"ZAP-70 shapes the immune microenvironment in B cell malignancies","volume":"10","author":"Chen","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.cca.2026.122858_bb0210","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1182\/blood-2007-05-092882","article-title":"Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia","volume":"112","author":"Rassenti","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.cca.2026.122858_bb0215","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.3324\/haematol.12710","article-title":"ZAP-70 mRNA expression provides clinically valuable information in early-stage chronic lymphocytic leukemia","volume":"93","author":"Reinoso-Mart\u00edn","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.cca.2026.122858_bb0220","doi-asserted-by":"crossref","first-page":"4088","DOI":"10.1200\/JCO.2010.33.9002","article-title":"Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia","volume":"29","author":"Wierda","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cca.2026.122858_bb0225","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(16)30029-8","volume":"17","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.cca.2026.122858_bb0230","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1038\/s41375-020-0727-y","article-title":"Prognostic model for newly diagnosed CLL patients in Binet stage a: results of the multicenter, prospective CLL1 trial of the German CLL study group","volume":"34","author":"Hoechstetter","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.cca.2026.122858_bb0235","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/sj.leu.2404458","article-title":"ZAP-70 expression, as detected by immunohistochemistry on bone marrow biopsies from early-phase CLL patients, is a strong adverse prognostic factor","volume":"21","author":"Zanotti","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.cca.2026.122858_bb0240","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1200\/JCO.2011.36.9348","article-title":"Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial","volume":"30","author":"B\u00f6ttcher","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cca.2026.122858_bb0245","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1182\/blood-2015-06-651125","article-title":"Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial","volume":"127","author":"Fischer","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.cca.2026.122858_bb0250","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.cca.2018.04.026","article-title":"ZAP-70 in chronic lymphocytic leukemia: a meta-analysis","volume":"483","author":"Liu","year":"2018","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.cca.2026.122858_bb0255","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/cyto.b.20106","article-title":"CD38 as a prognostic factor in B cell chronic lymphocytic leukaemia (B-CLL): comparison of three approaches to analyze its expression","volume":"70","author":"Boonstra","year":"2006","journal-title":"Cytometry B Clin. Cytom."},{"key":"10.1016\/j.cca.2026.122858_bb0260","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.3324\/haematol.13103","article-title":"CD49d expression is an independent risk factor of progressive disease in early stage chronic lymphocytic leukemia","volume":"93","author":"Rossi","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.cca.2026.122858_bb0265","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1200\/JCO.2013.50.8515","article-title":"CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemia","volume":"32","author":"Bulian","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cca.2026.122858_bb0270","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.leukres.2010.10.022","article-title":"CD49d is an independent prognostic marker that is associated with CXCR4 expression in CLL","volume":"35","author":"Majid","year":"2011","journal-title":"Leuk. Res."},{"key":"10.1016\/j.cca.2026.122858_bb0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.105049","article-title":"Prognostic value of CD49d in CLL: systematic review and meta-analysis","volume":"217","author":"Liman\u00f3wka","year":"2026","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.cca.2026.122858_bb0280","doi-asserted-by":"crossref","first-page":"215","DOI":"10.3324\/haematol.11622","article-title":"Multicenter study of ZAP-70 expression in patients with B-cell chronic lymphocytic leukemia using an optimized flow cytometry method","volume":"93","author":"Gachard","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.cca.2026.122858_bb0285","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1179\/1607845412Y.0000000015","article-title":"Pitfalls and limitations of ZAP-70 detection in chronic lymphocytic leukemia","volume":"17","author":"Vroblova","year":"2012","journal-title":"Hematology"},{"key":"10.1016\/j.cca.2026.122858_bb0290","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1182\/blood-2015-07-659144","article-title":"Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia","volume":"127","author":"Nadeu","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.cca.2026.122858_bb0295","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16152732","article-title":"Chronic lymphocytic leukemia: prognostic factors in the era of novel drugs","volume":"16","author":"Urso","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.cca.2026.122858_bb0300","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/cyto.b.20350","article-title":"National standardization of ZAP-70 determination by flow cytometry: the French experience","volume":"72","author":"Le Garff-Tavernier","year":"2007","journal-title":"Cytometry B Clin. Cytom."},{"key":"10.1016\/j.cca.2026.122858_bb0305","doi-asserted-by":"crossref","DOI":"10.1186\/1479-5876-8-23","article-title":"Prognostic impact of ZAP-70 expression in chronic lymphocytic leukemia: mean fluorescence intensity T\/B ratio versus percentage of positive cells","volume":"8","author":"Rossi","year":"2010","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.cca.2026.122858_bb0310","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/cyto.b.20078","article-title":"Quantitative flow cytometry of ZAP-70 levels in chronic lymphocytic leukemia using molecules of equivalent soluble fluorochrome","volume":"70","author":"Kay","year":"2006","journal-title":"Cytometry B Clin. Cytom."},{"key":"10.1016\/j.cca.2026.122858_bb0315","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/cyto.b.20622","article-title":"Combined normal donor and CLL: single tube ZAP-70 analysis","volume":"82","author":"Degheidy","year":"2012","journal-title":"Cytometry B Clin. Cytom."},{"key":"10.1016\/j.cca.2026.122858_bb0320","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/cyto.b.20121","article-title":"ZAP-70 by flow cytometry: a comparison of different antibodies, anticoagulants, and methods of analysis","volume":"70","author":"Best","year":"2006","journal-title":"Cytometry B Clin. Cytom."},{"key":"10.1016\/j.cca.2026.122858_bb0325","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/cyto.b.21138","article-title":"Prognostic value of ZAP-70 expression in chronic lymphocytic leukemia as assessed by quantitative polymerase chain reaction and flow cytometry","volume":"86","author":"Adams","year":"2014","journal-title":"Cytometry B Clin. Cytom."},{"key":"10.1016\/j.cca.2026.122858_bb0330","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1136\/jcp.2006.039586","article-title":"B cell chronic lymphocytic leukaemia\/small lymphocytic lymphoma: role of ZAP70 determination on bone marrow biopsy specimens","volume":"60","author":"Sabattini","year":"2007","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.cca.2026.122858_bb0335","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s00432-012-1177-3","article-title":"Quantification of ZAP-70 mRNA by real-time PCR is a prognostic factor in chronic lymphocytic leukemia","volume":"138","author":"Wang","year":"2012","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.cca.2026.122858_bb0340","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1002\/cyto.b.20591","article-title":"Methodological comparison of two anti-ZAP-70 antibodies","volume":"80","author":"Degheidy","year":"2011","journal-title":"Cytometry B Clin. Cytom."},{"key":"10.1016\/j.cca.2026.122858_bb0345","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.htct.2019.07.006","article-title":"Multidisciplinary diagnostics of chronic lymphocytic leukemia: European research initiative on CLL - ERIC recommendations","volume":"42","author":"Zalcberg","year":"2020","journal-title":"Hematol. Transfus. Cell Ther."},{"key":"10.1016\/j.cca.2026.122858_bb0350","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/ajh.23729","article-title":"Prospective validation of a risk score based on biological markers for predicting progression free survival in Binet stage a chronic lymphocytic leukemia patients: results of the multicenter O-CLL1-GISL study","volume":"89","author":"Gentile","year":"2014","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.cca.2026.122858_bb0355","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1038\/s41375-025-02615-5","article-title":"ATM aberrations in chronic lymphocytic leukemia: del(11q) rather than ATM mutations is an adverse-prognostic biomarker","volume":"39","author":"Thorvaldsdottir","year":"2025","journal-title":"Leukemia"},{"key":"10.1016\/j.cca.2026.122858_bb0360","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1182\/bloodadvances.2022009040","article-title":"Differential prognosis of single and multiple TP53 abnormalities in high-count MBL and untreated CLL","volume":"7","author":"Griffin","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.cca.2026.122858_bb0365","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.3324\/haematol.2018.212571","article-title":"Prognostic significance of translocations in the presence of mutated IGHV and of cytogenetic complexity at diagnosis of chronic lymphocytic leukemia","volume":"106","author":"Heerema","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.cca.2026.122858_bb0370","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13045-016-0320-z","article-title":"Extensive next-generation sequencing analysis in chronic lymphocytic leukemia at diagnosis: clinical and biological correlations","volume":"9","author":"Rigolin","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.cca.2026.122858_bb0375","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1038\/leu.2017.34","article-title":"Leukemia-cell proliferation and disease progression in patients with early stage chronic lymphocytic leukemia","volume":"31","author":"Murphy","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.cca.2026.122858_bb0380","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1055\/s-0042-1748828","article-title":"Flow cytometric expression of CD49d in newly diagnosed chronic lymphocytic leukemia and its correlation with established prognostic markers","volume":"14","author":"Kunnumbrath","year":"2022","journal-title":"J. Lab. Physicians"},{"key":"10.1016\/j.cca.2026.122858_bb0385","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1569707","article-title":"CD38 prognostic role in chronic lymphocytic leukemia patients treated with standard chemotherapy or targeted agents: a monocentric real-life experience","volume":"15","author":"Mettivier","year":"2025","journal-title":"Front. Oncol."},{"key":"10.1016\/j.cca.2026.122858_bb0390","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16223744","article-title":"Beta-2-microglobulin maintains overall survival prediction in Binet a stage chronic lymphocytic leukemia patients with compromised kidney function in both treatment eras of Chemoimmunotherapy and targeted agents","volume":"16","author":"Bohn","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.cca.2026.122858_bb0395","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41467-019-14225-8","article-title":"Machine learning can identify newly diagnosed patients with CLL at high risk of infection","volume":"11","author":"Agius","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cca.2026.122858_bb0400","doi-asserted-by":"crossref","first-page":"4649","DOI":"10.1007\/s00277-025-06595-5","article-title":"Real-world study on patient characteristics, treatment patterns and outcomes for treated patients with chronic lymphocytic leukemia during 2013\u20132022 in Finland","volume":"104","author":"Ranti","year":"2025","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.cca.2026.122858_bb0405","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1002\/ajh.24808","article-title":"IGHV mutational status testing in chronic lymphocytic leukemia","volume":"92","author":"Crombie","year":"2017","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.cca.2026.122858_bb0410","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1182\/blood.2020010536","article-title":"The impact of increasing karyotypic complexity and evolution on survival in patients with CLL treated with ibrutinib","volume":"138","author":"Kittai","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.cca.2026.122858_bb0415","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1200\/JCO.2011.39.3090","article-title":"Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia","volume":"30","author":"Claus","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cca.2026.122858_bb0420","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1080\/15592294.2016.1178432","article-title":"Prognostic impact of epigenetic classification in chronic lymphocytic leukemia: the case of subset #2","volume":"11","author":"Bhoi","year":"2016","journal-title":"Epigenetics"},{"key":"10.1016\/j.cca.2026.122858_bb0425","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0012780","article-title":"A molecular score by quantitative PCR as a new prognostic tool at diagnosis for chronic lymphocytic leukemia patients","volume":"5","author":"Stamatopoulos","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.cca.2026.122858_bb0430","article-title":"Genome-wide DNA methylation profiling in chronic lymphocytic leukaemia","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Genet."},{"key":"10.1016\/j.cca.2026.122858_bb0435","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1182\/blood-2005-04-1718","article-title":"ZAP-70 expression is associated with enhanced ability to respond to migratory and survival signals in B-cell chronic lymphocytic leukemia (B-CLL)","volume":"107","author":"Richardson","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.cca.2026.122858_bb0440","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1182\/blood-2006-12-062265","article-title":"ZAP-70 enhances IgM signaling independent of its kinase activity in chronic lymphocytic leukemia","volume":"111","author":"Chen","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.cca.2026.122858_bb0445","doi-asserted-by":"crossref","first-page":"4760","DOI":"10.1182\/bloodadvances.2022008068","article-title":"Real-world prognostic testing and treatment patterns in CLL\/SLL: results from 1462 patients in the informCLL registry","volume":"7","author":"Mato","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.cca.2026.122858_bb0450","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/cncr.31738","article-title":"Real-world testing and treatment patterns in chronic lymphocytic leukemia: a SEER patterns of care analysis","volume":"125","author":"Seymour","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.cca.2026.122858_bb0455","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3324\/haematol.2011.060129","article-title":"NOTCH1 mutations in +12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of +12 CLL","volume":"97","author":"Del Giudice","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.cca.2026.122858_bb0460","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1365-2141.2008.07166.x","article-title":"Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndrome","volume":"142","author":"Rossi","year":"2008","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.cca.2026.122858_bb0465","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/bjh.12458","article-title":"Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients","volume":"162","author":"Parikh","year":"2013","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.cca.2026.122858_bb0470","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines14020347","article-title":"Molecular pathogenesis and targeted treatment of Richter transformation","volume":"14","author":"Maher","year":"2026","journal-title":"Biomedicines"},{"key":"10.1016\/j.cca.2026.122858_bb0475","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.1158\/1078-0432.CCR-08-3266","article-title":"Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndrome","volume":"15","author":"Rossi","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cca.2026.122858_bb0480","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1002\/cyto.b.20136","article-title":"A standardized ZAP-70 assay--lessons learned in the trenches","volume":"70","author":"Shults","year":"2006","journal-title":"Cytometry B Clin. Cytom."},{"key":"10.1016\/j.cca.2026.122858_bb0485","first-page":"1","article-title":"ZAP-70, IgVh, and cytogenetics for assessing prognosis in chronic lymphocytic leukemia","volume":"6","author":"Trojani","year":"2010","journal-title":"Cancer Biomark."},{"key":"10.1016\/j.cca.2026.122858_bb0490","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/j.1751-553X.2010.01263.x","article-title":"MFI ratio estimation of ZAP-70 in B-CLL by flow cytometry can be improved by considering the isotype-matched antibody signal","volume":"33","author":"Marquez","year":"2011","journal-title":"Int. J. Lab. Hematol."}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898126020401?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898126020401?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:48:27Z","timestamp":1790704107000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898126020401"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,3]]},"references-count":98,"alternative-id":["S0009898126020401"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2026.122858","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2027,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ZAP-70 as a prognostic laboratory biomarker in chronic lymphocytic leukemia: flow-cytometric assessment, clinical utility, and standardization challenges","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2026.122858","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"122858"}}